A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Clinical trial NCT07503340 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07503340
- Sponsor
- Hoffmann-La Roche
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-01
- Primary completion
- 2029-08-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.